Featured Cases

If you took GranuFlo and Naturalyte and underwent hemodialysis and suffered any serious adverse health effects, please call (877) 800-1450 to speak to Finkelstein Thompson LLP attorneys who are available to analyze your situation at no cost or obligation to you. If you do not know if Granuflo was used for your hemodialysis treatment, Finkelstein Thompson LLP can even help you learn that information.

GranuFlo and Naturalyte are used to treat acute and chronic renal (kidney) failure during hemodialysis. The Food and Drug Administration ("FDA") recalled the drugs after they were linked to serious adverse health effects.  These drugs were part of a Class I recall which are the most serious type of recall issued by the FDA.  Class I recalls involve situations in which there is a reasonable probability that use of the recalled products will cause serious adverse health consequences or death. Indeed, as a result of the formulation of Naturalyte and GranuFlo, it is believed patients were at a higher risk of heart and cardiovascular injuries, including cardiac arrest, heart attacks, congestive heart failure, and death.

Finkelstein Thompson LLP is investigating allegations that Medtronic, Inc. illegally promoted and attempted to conceal the adverse events associated with InFUSE® Bone Graft ("InFUSE"), Medtronic, Inc.'s bio-engineered bone graft device used for spinal surgery. It is alleged that Medtronic, Inc. illegally promoted the off-label use of InFUSE for posterior lumbar surgery, when InFUSE is FDA-approved for anterior or abdominal lumbar surgery. It is also alleged that Medtronic, Inc. intentionally minimized or downplayed the risks of serious side effects related to the use of InFUSE, including ectopic or uncontrolled bone growth, inflammatory reactions, back and leg pain events, urinary retention, retrograde ejaculation, and implant displacement.

If you experienced complications from the use of InFUSE and wish to discuss your rights or provide information to assist the investigation, Finkelstein Thompson LLP welcomes your call. Finkelstein Thompson's Washington, D.C. office can be reached at (877)337-1050, or by email at This email address is being protected from spam bots, you need Javascript enabled to view it

Finkelstein Thompson LLP ("FT") is investigating patient claims as a result of receiving potentially contaminated steroid injections into the spinal area.  FT is also investigating claims of fungal infections from steroid injections into peripheral joint spaces, such as knees, shoulders, or ankles.

According to the CDC, healthcare facilities in twenty-three states were shipped lots of the contaminated steroids.  A list of those facilities can be found at the CDC's website.  The infected patients identified as of October 14, 2012, had all received the preservative-free (PF) methylprednisolone acetate (80mg/ml) injection from the three lots voluntarily recalled by the New England Compounding Center in Framingham, Massachusetts, on September 26, 2012.

If you believe you may have received one of the contaminated steroid injections and wish to discuss your rights or provide information to assist the investigation, Finkelstein Thompson LLP welcomes your call. Finkelstein Thompson's Washington, D.C. office can be reached at (877)337-1050, or by email at This email address is being protected from spam bots, you need Javascript enabled to view it